Interleukin-23 vs. interleukin-12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network
J Am Acad Dermatol 2024 Nov;91:889–895 doi: 10.1016/j.jaad.2024.07.1473
Tsai et al. observed no significant difference in the incidence of psoriatic arthritis among psoriasis patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors, although there was a numerically lower PsA risk with IL-23 inhibitors. Results indicate both therapies are similarly effective for PsO management.
The study involved a propensity-matched retrospective cohort analysis of psoriasis patients from the TriNetX network, assessing the incidence of PsA development in those treated with either IL-23 or IL-12/23 inhibitors. The study aimed to clarify the comparative risk of PsA with these biologics.